Hypertension

High blood pressure increases a patient's risk of heart attack, stroke and other diseases. Most people with hypertension have no symptoms. The Centers for Disease Control and Prevention (CDC) says nearly half of U.S. adults have hypertension, or high blood pressure, and only about 1 in 4 of those individuals has their hypertension under control. The World Health Organization (WHO) expects the epidemic of hypertension world-wide will exceed 1.56 billion people by 2025. Major efforts are underway to better control this primary risk factor through screenings, medication and invasive procedures such as renal denervation in severely uncontrolled patients.

Heart attack deaths are way down after decades of breakthroughs—but other risks have skyrocketed
Researchers explored more than 52 years of data, highlighting several key trends in the Journal of the American Heart Association.
FDA approves 3-in-1 polypill for hypertension
Widaplik, the new polypill from George Medicines, includes telmisartan, amlodipine and indapamide. The FDA's decision comes after positive data were published in both JACC and The Lancet.
Study finds 35 million patients may be eligible for renal denervation
However, eligibility alone does not mean a patient will benefit from treatment.
Cuffless blood pressure measurement devices: Convenient, but not ready for clinical use
Cuffless BP measurements could potentially provide significant value for clinicians and patients alike. It is still too early, however, for these technologies to be used in a clinical setting; too many unanswered questions remain.
Rates of obesity, high blood pressure and diabetes keep climbing in US
As time goes on, the gaps between the healthiest states and the least healthy states are only getting wider and wider. "Our findings highlight the urgent need for targeted strategies to reduce state-based inequities in cardiometabolic risk factors,” researchers wrote.

The Pulnovo pulmonary artery denervation catheter. In February 2021, the devices was granted the U.S. Food and Drug Administration (FDA) breakthrough device designation. #TCT2022 #PAH

Pulmonary artery denervation shows promise to treat pulmonary arterial hypertension

Pulmonary artery denervation may offer a new therapy option for this difficult-to-treat population.

Cardiologists sound the alarm as ‘staggering’ new data suggest CVD rates in the U.S. will rise dramatically

New data from the CDC and U.S. Census Bureau show just how bad CVD rates could get in the next few decades. Specialists agree that a lot of work is needed to help keep these estimates from becoming a reality.

High blood pressure more than doubles risk of COVID-19 hospitalization

Adults that received three doses of an mRNA COVID vaccine were 2.6 times as likely to be hospitalized if they also had high blood pressure.

RAAS inhibitors lower risk of aneurysm rupture among patients with high blood pressure

Researchers also noted that uncontrolled hypertension, exposure to second-hand smoke and untreated type 2 diabetes were all associated with a greater rupture risk.

cocaine heart failure HFrEF LVEF hospitalizations beta-blockers hypertension cardiology

How cocaine use affects outcomes for hospitalized heart failure patients

When cocaine users are hospitalized for heart failure, what should physicians expect? Are beta-blockers an effective treatment strategy?

Renal denervation is associated with improved blood pressure (BP) control and a reduced risk of adverse cardiovascular outcomes, according to two late-breaking clinical trials presented at EuroPCR 2022 in Paris. Both clinical trials focused on three-year data related to Medtronic’s Symplicity Spyral Renal Denervation (RDN) System, which was designed to lower BP through the use of a curling catheter that ablates overactive nerves.

Renal denervation improves blood pressure control, lowers risk of adverse cardiovascular outcomes

Two late-breaking clinical trials at EuroPCR 2022 in Paris focused on the potential benefits of renal denervation.

Arterial stiffness may predict type 2 diabetes risk better than high blood pressure

Researchers tracked data from more than 11,000 adult patients, sharing their findings in Hypertension.

Links to the ACC.22 late-breaking clinical trials

Learn more about the late-breaking studies presented at ACC.22 in Washington, D.C.

Hypertension

Heart attack deaths are way down after decades of breakthroughs—but other risks have skyrocketed

FDA approves 3-in-1 polypill for hypertension

Study finds 35 million patients may be eligible for renal denervation

Cuffless blood pressure measurement devices: Convenient, but not ready for clinical use

Rates of obesity, high blood pressure and diabetes keep climbing in US